{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:08:27Z","timestamp":1793941707110,"version":"4.8.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1A2C1091563"],"award-info":[{"award-number":["2022R1A2C1091563"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-02293074"],"award-info":[{"award-number":["RS-2025-02293074"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-25441283"],"award-info":[{"award-number":["RS-2025-25441283"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002560","name":"Soonchunhyang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272656"],"award-info":[{"award-number":["82272656"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260502"],"award-info":[{"award-number":["82260502"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32370779"],"award-info":[{"award-number":["32370779"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004761","name":"Provincial Natural Science Foundation of Hunan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hunan Provincial Postgraduate Research and Innovation Project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Breast cancer remains the leading cause of cancer-related mortality among women worldwide. Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as a critical therapeutic option, particularly for patients with triple-negative breast cancer and other HER2-negative metastatic breast cancer harboring\n                    <jats:italic>BRCA<\/jats:italic>\n                    mutations. Despite their clinical success, the emergence of primary and acquired resistance to PARP inhibitors poses a significant challenge, limiting their long-term effectiveness. Here we provide a comprehensive overview of the mechanisms underlying the action of PARP inhibitors, as well as their clinical development and application. In addition, we discuss the factors driving resistance and potential strategies to overcome it in the context of PARP inhibitors.\n                  <\/jats:p>","DOI":"10.1038\/s12276-026-01673-8","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T09:17:17Z","timestamp":1775812637000},"page":"981-992","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["PARP inhibitors and breast cancer: from therapeutic breakthrough to resistance challenge"],"prefix":"10.1038","volume":"58","author":[{"given":"Weiyun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghui","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liujun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinhao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4364-3260","authenticated-orcid":false,"given":"Wootae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3841-8716","authenticated-orcid":false,"given":"Fei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"1673_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","volume":"31","author":"J Kim","year":"2025","unstructured":"Kim, J. et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat. Med. 31, 1154\u20131162 (2025).","journal-title":"Nat. Med."},{"key":"1673_CR2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1101\/gad.334516.119","volume":"34","author":"D Slade","year":"2020","unstructured":"Slade, D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 34, 360\u2013394 (2020).","journal-title":"Genes Dev."},{"key":"1673_CR3","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt, A. N. J. et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N. Engl. J. Med. 384, 2394\u20132405 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1673_CR4","doi-asserted-by":"publisher","first-page":"5756","DOI":"10.3390\/cancers13225756","volume":"13","author":"P DiSilvestro","year":"2021","unstructured":"DiSilvestro, P. et al. Maintenance treatment of newly diagnosed advanced ovarian cancer: time for a paradigm shift?. Cancers 13, 5756 (2021).","journal-title":"Cancers"},{"key":"1673_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","volume":"16","author":"L Cortesi","year":"2021","unstructured":"Cortesi, L., Rugo, H. S. & Jackisch, C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 16, 255\u2013282 (2021).","journal-title":"Target Oncol."},{"key":"1673_CR6","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.3390\/cancers14174332","volume":"14","author":"MCS Menezes","year":"2022","unstructured":"Menezes, M. C. S., Raheem, F., Mina, L., Ernst, B. & Batalini, F. PARP inhibitors for breast cancer: germline BRCA1\/2 and beyond. Cancers 14, 4332 (2022).","journal-title":"Cancers"},{"key":"1673_CR7","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/JCO.2010.34.2980","volume":"29","author":"B Norquist","year":"2011","unstructured":"Norquist, B. et al. Secondary somatic mutations restoring BRCA1\/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29, 3008\u20133015 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1673_CR8","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1093\/nar\/gkz120","volume":"47","author":"EE Alemasova","year":"2019","unstructured":"Alemasova, E. E. & Lavrik, O. I. Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins. Nucleic Acids Res. 47, 3811\u20133827 (2019).","journal-title":"Nucleic Acids Res."},{"key":"1673_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13053-014-0024-8","volume":"13","author":"M Anwar","year":"2015","unstructured":"Anwar, M., Aslam, H. M. & Anwar, S. PARP inhibitors. Hered. Cancer Clin. Pract. 13, 4 (2015).","journal-title":"Hered. Cancer Clin. Pract."},{"key":"1673_CR10","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41586-025-08749-x","volume":"640","author":"S Lahiri","year":"2025","unstructured":"Lahiri, S. et al. BRCA2 prevents PARPi-mediated PARP1 retention to protect RAD51 filaments. Nature 640, 1103\u20131111 (2025).","journal-title":"Nature"},{"key":"1673_CR11","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1101\/gad.348479.121","volume":"35","author":"A Simoneau","year":"2021","unstructured":"Simoneau, A., Xiong, R. & Zou, L. The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1\/2-deficient cells. Genes Dev. 35, 1271\u20131289 (2021).","journal-title":"Genes Dev."},{"key":"1673_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1158\/1541-7786.MCR-18-0138","volume":"17","author":"TA Hopkins","year":"2019","unstructured":"Hopkins, T. A. et al. PARP1 trapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow. Mol. Cancer Res. 17, 409\u2013419 (2019).","journal-title":"Mol. Cancer Res."},{"key":"1673_CR13","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.chembiol.2023.12.019","volume":"31","author":"AA Gopal","year":"2024","unstructured":"Gopal, A. A., Fernandez, B., Delano, J., Weissleder, R. & Dubach, J. M. PARP trapping is governed by the PARP inhibitor dissociation rate constant. Cell Chem. Biol. 31, 1373\u20131382 (2024).","journal-title":"Cell Chem. Biol."},{"key":"1673_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","volume":"13","author":"J Murai","year":"2014","unstructured":"Murai, J. et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol. Cancer Ther. 13, 433\u2013443 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"1673_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","volume":"628","author":"M Petropoulos","year":"2024","unstructured":"Petropoulos, M. et al. Transcription\u2013replication conflicts underlie sensitivity to PARP inhibitors. Nature 628, 433\u2013441 (2024).","journal-title":"Nature"},{"key":"1673_CR16","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai, J. et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72, 5588\u20135599 (2012).","journal-title":"Cancer Res."},{"key":"1673_CR17","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41419-024-07277-2","volume":"15","author":"L Chen","year":"2024","unstructured":"Chen, L. et al. Minimizing DNA trapping while maintaining activity inhibition via selective PARP1 degrader. Cell Death Dis. 15, 898 (2024).","journal-title":"Cell Death Dis."},{"key":"1673_CR18","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1016\/j.molcel.2021.06.011","volume":"81","author":"K Cong","year":"2021","unstructured":"Cong, K. et al. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Mol. Cell 81, 3128\u20133144 (2021).","journal-title":"Mol. Cell"},{"key":"1673_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202410718","volume":"12","author":"G Pai Bellare","year":"2025","unstructured":"Pai Bellare, G. et al. Targeting replication fork processing synergizes with PARP inhibition to potentiate lethality in homologous recombination proficient ovarian cancers. Adv. Sci. 12, e2410718 (2025).","journal-title":"Adv. Sci."},{"key":"1673_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41594-022-00747-1","volume":"29","author":"A Vaitsiankova","year":"2022","unstructured":"Vaitsiankova, A. et al. PARP inhibition impedes the maturation of nascent DNA strands during DNA replication. Nat. Struct. Mol. Biol. 29, 329\u2013338 (2022).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1673_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI181062","volume":"134","author":"X Li","year":"2024","unstructured":"Li, X. & Zou, L. BRCAness, DNA gaps, and gain and loss of PARP inhibitor-induced synthetic lethality. J. Clin. Invest. 134, e181062 (2024).","journal-title":"J. Clin. Invest."},{"key":"1673_CR22","doi-asserted-by":"publisher","first-page":"9531","DOI":"10.1021\/acs.jmedchem.2c00395","volume":"65","author":"C Li","year":"2022","unstructured":"Li, C. et al. Overview of methionine adenosyltransferase 2A (MAT2A) as an anticancer target: structure, function, and inhibitors. J. Med. Chem. 65, 9531\u20139547 (2022).","journal-title":"J. Med. Chem."},{"key":"1673_CR23","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.cell.2017.05.003","volume":"169","author":"KE Pendleton","year":"2017","unstructured":"Pendleton, K. E. et al. The U6 snRNA m(6)A methyltransferase METTL16 regulates SAM synthetase intron retention. Cell 169, 824\u2013835 (2017).","journal-title":"Cell"},{"key":"1673_CR24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI188120","volume":"135","author":"X Zeng","year":"2025","unstructured":"Zeng, X. et al. Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop. J. Clin. Invest. 135, e188120 (2025).","journal-title":"J. Clin. Invest."},{"key":"1673_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ccell.2019.05.014","volume":"36","author":"A Fedoriw","year":"2019","unstructured":"Fedoriw, A. et al. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. Cancer Cell 36, 100\u2013114 (2019).","journal-title":"Cancer Cell"},{"key":"1673_CR26","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou, C. et al. PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 9, 722\u2013737 (2019).","journal-title":"Cancer Discov."},{"key":"1673_CR27","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1158\/0008-5472.CAN-24-2531","volume":"10","author":"F Pedretti","year":"2025","unstructured":"Pedretti, F. et al. Harnessing STING signaling and natural killer cells overcomes PARP inhibitor resistance in homologous recombination-deficient breast cancer. Cancer Res. 10, 1888\u20131908 (2025).","journal-title":"Cancer Res."},{"key":"1673_CR28","doi-asserted-by":"crossref","unstructured":"A small-molecule PARP7 inhibitor triggers antitumor immunity. Cancer Discov. 11, 2125 (2021).","DOI":"10.1158\/2159-8290.CD-RW2021-107"},{"key":"1673_CR29","doi-asserted-by":"publisher","first-page":"A907","DOI":"10.1136\/jitc-2021-SITC2021.866","volume":"9","author":"K Kuplast-Barr","year":"2021","unstructured":"Kuplast-Barr, K. et al. 866 RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in preclinical models and patient tumors. Regul. Young Investig. Award Abstr. 9, A907 (2021).","journal-title":"Regul. Young Investig. Award Abstr."},{"key":"1673_CR30","doi-asserted-by":"publisher","first-page":"7917","DOI":"10.1158\/1078-0432.CCR-08-1223","volume":"14","author":"R Plummer","year":"2008","unstructured":"Plummer, R. et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 14, 7917\u20137923 (2008).","journal-title":"Clin. Cancer Res."},{"key":"1673_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","volume":"24","author":"Y Drew","year":"2025","unstructured":"Drew, Y., Zenke, F. T. & Curtin, N. J. DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications. Nat. Rev. Drug. Discov. 24, 19\u201339 (2025).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1673_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/978-3-319-91442-8_15","volume":"211","author":"S Bochum","year":"2018","unstructured":"Bochum, S., Berger, S. & Martens, U. M. Olaparib. Recent Results Cancer Res 211, 217\u2013233 (2018).","journal-title":"Recent Results Cancer Res"},{"key":"1673_CR33","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523\u2013533 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1673_CR34","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.annonc.2020.11.009","volume":"32","author":"HP Eikesdal","year":"2021","unstructured":"Eikesdal, H. P. et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann. Oncol. 32, 240\u2013249 (2021).","journal-title":"Ann. Oncol."},{"key":"1673_CR35","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1470-2045(20)30447-2","volume":"21","author":"V Di\u00e9ras","year":"2020","unstructured":"Di\u00e9ras, V. et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 1269\u20131282 (2020).","journal-title":"Lancet Oncol."},{"key":"1673_CR36","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ijc.34525","volume":"153","author":"E Senkus","year":"2023","unstructured":"Senkus, E. et al. Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: subgroup analyses from the phase III OlympiAD trial. Int. J. Cancer 153, 803\u2013814 (2023).","journal-title":"Int. J. Cancer"},{"key":"1673_CR37","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","volume":"30","author":"ME Robson","year":"2019","unstructured":"Robson, M. E. et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann. Oncol. 30, 558\u2013566 (2019).","journal-title":"Ann. Oncol."},{"key":"1673_CR38","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ygyno.2020.02.030","volume":"157","author":"JE Wolford","year":"2020","unstructured":"Wolford, J. E. et al. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma. Gynecol. Oncol. 157, 500\u2013507 (2020).","journal-title":"Gynecol. Oncol."},{"key":"1673_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16142-7","volume":"11","author":"N Chopra","year":"2020","unstructured":"Chopra, N. et al. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nat. Commun. 11, 2662 (2020).","journal-title":"Nat. Commun."},{"key":"1673_CR40","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ejca.2021.09.028","volume":"159","author":"A Patsouris","year":"2021","unstructured":"Patsouris, A. et al. Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1\/2 mutation. Eur. J. Cancer 159, 283\u2013295 (2021).","journal-title":"Eur. J. Cancer"},{"key":"1673_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00240-w","volume":"7","author":"M Kalra","year":"2021","unstructured":"Kalra, M. et al. Cisplatin +\/\u2212 rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer. NPJ Breast Cancer 7, 29 (2021).","journal-title":"NPJ Breast Cancer"},{"key":"1673_CR42","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s43018-022-00400-2","volume":"3","author":"LM Spring","year":"2022","unstructured":"Spring, L. M. et al. Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. Nat. Cancer 3, 927\u2013931 (2022).","journal-title":"Nat. Cancer"},{"key":"1673_CR43","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.2147\/IJWH.S466250","volume":"16","author":"A Gonzalez","year":"2024","unstructured":"Gonzalez, A., Kistenfeger, Q. & Cosgrove, C. M. Patient selection for the use of niraparib in advanced ovarian cancer: a review. Int. J. Womens Health 16, 2239\u20132246 (2024).","journal-title":"Int. J. Womens Health"},{"key":"1673_CR44","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1358\/dot.2019.55.7.3015642","volume":"55","author":"G Guney Eskiler","year":"2019","unstructured":"Guney Eskiler, G. Talazoparib to treat BRCA-positive breast cancer. Drugs Today 55, 459\u2013467 (2019).","journal-title":"Drugs Today"},{"key":"1673_CR45","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s40265-018-1026-z","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy, S. M. Talazoparib: first global approval. Drugs 78, 1939\u20131946 (2018).","journal-title":"Drugs"},{"key":"1673_CR46","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/jcph.1626","volume":"60","author":"M Elmeliegy","year":"2020","unstructured":"Elmeliegy, M. et al. Exposure-safety analyses of talazoparib in patients with advanced breast cancer and germline BRCA1\/2 mutations in the EMBRACA and ABRAZO trials. J. Clin. Pharmacol. 60, 1334\u20131343 (2020).","journal-title":"J. Clin. Pharmacol."},{"key":"1673_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116405","volume":"271","author":"X Peng","year":"2024","unstructured":"Peng, X. et al. High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders. Eur. J. Med. Chem. 271, 116405 (2024).","journal-title":"Eur. J. Med. Chem"},{"key":"1673_CR48","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(22)00739-2","volume":"24","author":"E Rodler","year":"2023","unstructured":"Rodler, E. et al. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 24, 162\u2013174 (2023).","journal-title":"Lancet Oncol."},{"key":"1673_CR49","doi-asserted-by":"publisher","first-page":"392","DOI":"10.2174\/1574892813666180305165256","volume":"13","author":"G Mittica","year":"2018","unstructured":"Mittica, G. et al. PARP inhibitors in ovarian cancer. Recent Pat. Anticancer Drug Discov. 13, 392\u2013410 (2018).","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"1673_CR50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.seminoncol.2023.09.005","volume":"51","author":"Y Zeng","year":"2024","unstructured":"Zeng, Y., Arisa, O., Peer, C. J., Fojo, A. & Figg, W. D. PARP inhibitors: a review of the pharmacology, pharmacokinetics, and pharmacogenetics. Semin. Oncol. 51, 19\u201324 (2024).","journal-title":"Semin. Oncol."},{"key":"1673_CR51","doi-asserted-by":"publisher","first-page":"370","DOI":"10.21147\/j.issn.1000-9604.2020.03.08","volume":"32","author":"H Li","year":"2020","unstructured":"Li, H. et al. Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. Chin. J. Cancer Res. 32, 370\u2013382 (2020).","journal-title":"Chin. J. Cancer Res."},{"key":"1673_CR52","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40265-021-01541-x","volume":"81","author":"A Lee","year":"2021","unstructured":"Lee, A. Fuzuloparib: first approval. Drugs 81, 1221\u20131226 (2021).","journal-title":"Drugs"},{"key":"1673_CR53","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10549-022-06785-z","volume":"197","author":"B Xu","year":"2023","unstructured":"Xu, B. et al. Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study. Breast Cancer Res. Treat. 197, 489\u2013501 (2023).","journal-title":"Breast Cancer Res. Treat."},{"key":"1673_CR54","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s40265-021-01552-8","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham, A. Pamiparib: first approval. Drugs 81, 1343\u20131348 (2021).","journal-title":"Drugs"},{"key":"1673_CR55","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.3390\/curroncol30020143","volume":"30","author":"M Tang","year":"2023","unstructured":"Tang, M., Pearson, S.-A., Simes, R. J. & Chua, B. H. Harnessing real-world evidence to advance cancer research. Curr. Oncol. 30, 1844\u20131859 (2023).","journal-title":"Curr. Oncol."},{"key":"1673_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.578095","volume":"10","author":"Y Han","year":"2020","unstructured":"Han, Y., Yu, X., Li, S., Tian, Y. & Liu, C. New perspectives for resistance to PARP inhibitors in triple-negative breast cancer. Front. Oncol. 10, 578095 (2020).","journal-title":"Front. Oncol."},{"key":"1673_CR57","doi-asserted-by":"publisher","first-page":"6708","DOI":"10.1158\/1078-0432.CCR-17-0544","volume":"23","author":"B Weigelt","year":"2017","unstructured":"Weigelt, B. et al. Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Clin. Cancer Res. 23, 6708\u20136720 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1673_CR58","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.clbc.2017.12.010","volume":"18","author":"EL Gornstein","year":"2018","unstructured":"Gornstein, E. L. et al. BRCA2 reversion mutation associated with acquired resistance to olaparib in estrogen receptor-positive breast cancer detected by genomic profiling of tissue and liquid biopsy. Clin. Breast Cancer 18, 184\u2013188 (2018).","journal-title":"Clin. Breast Cancer"},{"key":"1673_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22582-6","volume":"12","author":"EM Swisher","year":"2021","unstructured":"Swisher, E. M. et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (parts 1 and 2). Nat. Commun. 12, 2487 (2021).","journal-title":"Nat. Commun."},{"key":"1673_CR60","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/CCO.0000000000001092","volume":"36","author":"C Valenza","year":"2024","unstructured":"Valenza, C., Marsicano, R. M., Trapani, D. & Curigliano, G. PARP inhibitor resistant BRCA-mutated advanced breast cancer: current landscape and emerging treatments. Curr. Opin. Oncol. 36, 474\u2013479 (2024).","journal-title":"Curr. Opin. Oncol."},{"key":"1673_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05564-z","volume":"9","author":"O Kondrashova","year":"2018","unstructured":"Kondrashova, O. et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat. Commun. 9, 3970 (2018).","journal-title":"Nat. Commun."},{"key":"1673_CR62","first-page":"1075","volume":"108","author":"P Ter Brugge","year":"2022","unstructured":"Ter Brugge, P. et al. Corrigendum: mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer. J. Natl Cancer Inst. 108, 1075 (2022).","journal-title":"J. Natl Cancer Inst."},{"key":"1673_CR63","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1016\/j.molcel.2024.09.016","volume":"84","author":"C Grelloni","year":"2024","unstructured":"Grelloni, C. et al. BRCA1 levels and DNA-damage response are controlled by the competitive binding of circHIPK3 or FMRP to the BRCA1 mRNA. Mol. Cell 84, 4079\u20134094 (2024).","journal-title":"Mol. Cell"},{"key":"1673_CR64","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature18325","volume":"535","author":"A Ray Chaudhuri","year":"2016","unstructured":"Ray Chaudhuri, A. et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature 535, 382\u2013387 (2016).","journal-title":"Nature"},{"key":"1673_CR65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2422720122","volume":"122","author":"H Zhang","year":"2025","unstructured":"Zhang, H. et al. ATM priming and end resection-coupled phosphorylation of MRE11 is important for fork protection and replication restart. Proc. Natl Acad. Sci. USA 122, e2422720122 (2025).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1673_CR66","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nsmb.3252","volume":"23","author":"J Michl","year":"2016","unstructured":"Michl, J., Zimmer, J., Buffa, F. M., McDermott, U. & Tarsounas, M. FANCD2 limits replication stress and genome instability in cells lacking BRCA2. Nat. Struct. Mol. Biol. 23, 755\u2013757 (2016).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1673_CR67","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/ncb3626","volume":"19","author":"B Rondinelli","year":"2017","unstructured":"Rondinelli, B. et al. EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat. Cell Biol. 19, 1371\u20131378 (2017).","journal-title":"Nat. Cell Biol."},{"key":"1673_CR68","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp6567","volume":"10","author":"A Nespolo","year":"2024","unstructured":"Nespolo, A. et al. USP1 deubiquitinates PARP1 to regulate its trapping and PARylation activity. Sci. Adv. 10, eadp6567 (2024).","journal-title":"Sci. Adv."},{"key":"1673_CR69","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2426743122","volume":"122","author":"K Pappas","year":"2025","unstructured":"Pappas, K. et al. BRCA2 reversion mutation-independent resistance to PARP inhibition through impaired DNA prereplication complex function. Proc. Natl Acad. Sci. USA 122, e2426743122 (2025).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1673_CR70","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41586-025-09414-z","volume":"645","author":"SC Moser","year":"2025","unstructured":"Moser, S. C. et al. NASP modulates histone turnover to drive PARP inhibitor resistance. Nature 645, 1071\u20131080 (2025).","journal-title":"Nature"},{"key":"1673_CR71","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1158\/0008-5472.CAN-14-0839","volume":"75","author":"JE Jaspers","year":"2015","unstructured":"Jaspers, J. E. et al. BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance. Cancer Res. 75, 732\u2013741 (2015).","journal-title":"Cancer Res."},{"key":"1673_CR72","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3390\/cancers12061607","volume":"12","author":"M McMullen","year":"2020","unstructured":"McMullen, M., Karakasis, K., Madariaga, A. & Oza, A. M. Overcoming platinum and PARP-inhibitor resistance in ovarian cancer. Cancers 12, 1607 (2020).","journal-title":"Cancers"},{"key":"1673_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09312-9","volume":"10","author":"EL Christie","year":"2019","unstructured":"Christie, E. L. et al. Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer. Nat. Commun. 10, 1295 (2019).","journal-title":"Nat. Commun."},{"key":"1673_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02527-6","volume":"20","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q. et al. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer. BMC Med. 20, 321 (2022).","journal-title":"BMC Med."},{"key":"1673_CR75","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40265-023-01934-0","volume":"83","author":"V Garg","year":"2023","unstructured":"Garg, V. & Oza, A. M. Treatment of ovarian cancer beyond PARP inhibition: current and future options. Drugs 83, 1365\u20131385 (2023).","journal-title":"Drugs"},{"key":"1673_CR76","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/annonc\/mdx505","volume":"29","author":"HS Han","year":"2018","unstructured":"Han, H. S. et al. Veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in patients with BRCA1\/2 locally recurrent\/metastatic breast cancer: randomized phase II study. Ann. Oncol. 29, 154\u2013161 (2018).","journal-title":"Ann. Oncol."},{"key":"1673_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113580","volume":"200","author":"V Di\u00e9ras","year":"2024","unstructured":"Di\u00e9ras, V. et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): final overall survival results from a randomized phase 3 trial. Eur. J. Cancer 200, 113580 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1673_CR78","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1158\/1078-0432.CCR-16-2714","volume":"23","author":"G Somlo","year":"2017","unstructured":"Somlo, G. et al. Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: California Cancer Consortium Trial NCT01149083. Clin. Cancer Res. 23, 4066\u20134076 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1673_CR79","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.3390\/jcm12041588","volume":"12","author":"W Sun","year":"2023","unstructured":"Sun, W., Wu, Y., Ma, F., Fan, J. & Qiao, Y. Efficacy of PARP inhibitor, platinum, and immunotherapy in BRCA-mutated HER2-negative breast cancer patients: a systematic review and network meta-analysis. J. Clin. Med. 12, 1588 (2023).","journal-title":"J. Clin. Med."},{"key":"1673_CR80","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","volume":"23","author":"S Jiao","year":"2017","unstructured":"Jiao, S. et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin. Cancer Res. 23, 3711\u20133720 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1673_CR81","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3390\/cells14040314","volume":"14","author":"R Huang","year":"2025","unstructured":"Huang, R. et al. A critical role of intracellular PD-L1 in promoting ovarian cancer progression. Cells 14, 314 (2025).","journal-title":"Cells"},{"key":"1673_CR82","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10585-024-10307-0","volume":"41","author":"Q Zheng","year":"2024","unstructured":"Zheng, Q., Zhou, T. & Ding, W. Efficacy and safety of PARPis combined with an ICIs for advanced or metastatic triple-negative breast cancer: a single-arm meta-analysis. Clin. Exp. Metastasis 41, 843\u2013850 (2024).","journal-title":"Clin. Exp. Metastasis"},{"key":"1673_CR83","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2083755","volume":"11","author":"AD Staniszewska","year":"2022","unstructured":"Staniszewska, A. D. et al. PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors. Oncoimmunology 11, 2083755 (2022).","journal-title":"Oncoimmunology"},{"key":"1673_CR84","doi-asserted-by":"publisher","DOI":"10.1177\/10732748241298329","volume":"31","author":"Z Lin","year":"2024","unstructured":"Lin, Z., Wang, L., Xing, Z., Wang, F. & Cheng, X. Update on combination strategies of PARP inhibitors. Cancer Control 31, 10732748241298329 (2024).","journal-title":"Cancer Control"},{"key":"1673_CR85","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","volume":"5","author":"S Vinayak","year":"2019","unstructured":"Vinayak, S. et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 5, 1132\u20131140 (2019).","journal-title":"JAMA Oncol."},{"key":"1673_CR86","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaoncol.2022.5228","volume":"9","author":"TA Yap","year":"2023","unstructured":"Yap, T. A. et al. Avelumab plus talazoparib in patients with advanced solid tumors. JAMA Oncol. 9, 40\u201350 (2023).","journal-title":"JAMA Oncol."},{"key":"1673_CR87","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2020.3","volume":"22","author":"HL Smith","year":"2020","unstructured":"Smith, H. L., Southgate, H., Tweddle, D. A. & Curtin, N. J. DNA damage checkpoint kinases in cancer. Expert Rev. Mol. Med. 22, e2 (2020).","journal-title":"Expert Rev. Mol. Med."},{"key":"1673_CR88","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.molcel.2020.04.035","volume":"78","author":"JM Cleary","year":"2020","unstructured":"Cleary, J. M., Aguirre, A. J., Shapiro, G. I. & D\u2019Andrea, A. D. Biomarker-guided development of DNA repair inhibitors. Mol. Cell. 78, 1070\u20131085 (2020).","journal-title":"Mol. Cell."},{"key":"1673_CR89","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s11523-024-01102-8","volume":"19","author":"EP Hamilton","year":"2024","unstructured":"Hamilton, E. P. et al. Adavosertib in combination with olaparib in patients with refractory solid tumors: an open-label, dose-finding, and dose-expansion phase Ib trial. Target. Oncol. 19, 879\u2013892 (2024).","journal-title":"Target. Oncol."},{"key":"1673_CR90","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.ccell.2019.05.001","volume":"35","author":"Y Fang","year":"2019","unstructured":"Fang, Y. et al. Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy. Cancer Cell 35, 851\u2013867 (2019).","journal-title":"Cancer Cell"},{"key":"1673_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109978","volume":"27","author":"H Xu","year":"2024","unstructured":"Xu, H. et al. CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. iScience 27, 109978 (2024).","journal-title":"iScience"},{"key":"1673_CR92","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1158\/2159-8290.CD-12-0433","volume":"2","author":"FL Rehman","year":"2012","unstructured":"Rehman, F. L., Lord, C. J. & Ashworth, A. The promise of combining inhibition of PI3K and PARP as cancer therapy. Cancer Discov. 2, 982\u2013984 (2012).","journal-title":"Cancer Discov."},{"key":"1673_CR93","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","volume":"2","author":"YH Ibrahim","year":"2012","unstructured":"Ibrahim, Y. H. et al. PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2, 1036\u20131047 (2012).","journal-title":"Cancer Discov."},{"key":"1673_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.110229","volume":"91","author":"G Guney Eskiler","year":"2022","unstructured":"Guney Eskiler, G. & Ozturk, M. Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor talazoparib combination in BRCA-deficient triple negative breast cancer cells. Cell. Signal. 91, 110229 (2022).","journal-title":"Cell. Signal."},{"key":"1673_CR95","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.chembiol.2021.02.010","volume":"28","author":"LB Schenkel","year":"2021","unstructured":"Schenkel, L. B. et al. A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants. Cell Chem. Biol. 28, 1158\u20131168 (2021).","journal-title":"Cell Chem. Biol."},{"key":"1673_CR96","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1200\/JCO.20.02151","volume":"38","author":"NM Tung","year":"2020","unstructured":"Tung, N. M. et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J. Clin. Oncol. 38, 4274\u20134282 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1673_CR97","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1093\/annonc\/mdy257","volume":"29","author":"J Ettl","year":"2018","unstructured":"Ettl, J. et al. Quality of life with talazoparib versus physician\u2019s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1\/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann. Oncol. 29, 1939\u20131947 (2018).","journal-title":"Ann. Oncol."},{"key":"1673_CR98","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz085","volume":"4","author":"HS Rugo","year":"2020","unstructured":"Rugo, H. S. et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician\u2019s choice standard-of-care chemotherapy. JNCI Cancer Spectr. 4, pkz085 (2020).","journal-title":"JNCI Cancer Spectr."},{"key":"1673_CR99","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl, S. et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 19, 497\u2013509 (2018).","journal-title":"Lancet Oncol."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01673-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01673-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01673-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:05:46Z","timestamp":1782716746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01673-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":99,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1673"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01673-8","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}